{"entity":{"id":"sstr5","kind":"target","name":"SSTR5","aka":["somatostatin receptor 5","Somatostatin receptor type 5"],"tldr":"SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","summary":"Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Pasireotide. Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.00, clinical 0.91). In OnCo, 1 product record names it (Pasireotide).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11334","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11334"},{"label":"UniProt P35346","url":"https://www.uniprot.org/uniprotkb/P35346/entry"},{"label":"NCBI Gene 6755","url":"https://www.ncbi.nlm.nih.gov/gene/6755"},{"label":"Ensembl ENSG00000162009","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162009"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["pasireotide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"SSTR5","role":["drug-target","biomarker"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:11334","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11334","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P35346","url":"https://www.uniprot.org/uniprotkb/P35346/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene SSTR5","url":"https://civicdb.org/features/5499","note":"1 evidence items, 0 assertions, 2 variants; diseases: Neuroendocrine Tumour (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000162009","url":"https://platform.opentargets.org/target/ENSG00000162009/associations","note":"association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.60 (GraphQL API, CC0)"}],"hgnc":"HGNC:11334","ensembl":"ENSG00000162009","uniprot":"P35346","entrez":"6755","biology":"Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation. Location: Cell membrane (UniProt). Locus 16p13.3 (HGNC).","whereFound":["Neuroendocrine tumours: Open Targets association 0.60 with neuroendocrine neoplasm (MONDO_0019496); CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/sstr5/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"}]}}